- Home
- PTCT
as 06-20-2025 3:40pm EST
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 3.7B | IPO Year: | 2013 |
| Target Price: | $63.57 | AVG Volume (30 days): | 939.9K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.72 - $58.38 | Next Earning Date: | 08-07-2025 |
| Revenue: | $1,772,758,000 | Revenue Growth: | 91.12% |
| Revenue Growth (this year): | 121.5% | Revenue Growth (next year): | -51.24% |
Stock Insider Trading Activity of PTC Therapeutics Inc. (PTCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | May 15 '25 | Sell | $46.10 | 2,812 | $129,716.88 | 103,901 | |
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Apr 22 '25 | Sell | $48.74 | 2,804 | $136,655.74 | 273,234 | |
| Golden Lee Scott | PTCT | EVP & CHIEF MEDICAL OFFICER | Apr 2 '25 | Sell | $46.95 | 897 | $42,114.15 | 75,997 |
Latest PTC Therapeutics Inc. News
PTCT Breaking Stock News: Dive into PTCT Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
15 days ago
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy
MT Newswires
17 days ago
RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating
Yahoo Finance
21 days ago
This week in Trumponomics: Too bad TACO isn’t true
The Guardian
21 days ago
Starmer says Farage would spook the City and give us Truss 2 – he could be right
Yahoo Finance Video
21 days ago
AI ecosystem isn't just Nvidia: Unlock it further with this ETF
Reuters
21 days ago
Ford recalls more than 29,000 vehicles in the US, NHTSA says
USA TODAY
21 days ago
Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states
Compare PTCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTCT PTC Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.